FY2024 Earnings Forecast for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities research analysts at HC Wainwright cut their FY2024 EPS estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($0.76) for the year, down from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q4 2024 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at ($0.47) EPS.

Several other equities research analysts also recently weighed in on LXRX. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Trading Down 8.0 %

Shares of Lexicon Pharmaceuticals stock opened at $0.98 on Friday. The stock has a market cap of $240.13 million, a PE ratio of -1.36 and a beta of 1.24. The firm has a fifty day moving average price of $1.63 and a 200 day moving average price of $1.74. Lexicon Pharmaceuticals has a 1 year low of $0.97 and a 1 year high of $3.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 11.51 and a quick ratio of 11.49.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Barclays PLC raised its holdings in Lexicon Pharmaceuticals by 391.6% in the 3rd quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 154,436 shares during the period. XTX Topco Ltd acquired a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $126,000. State Street Corp lifted its position in shares of Lexicon Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock valued at $3,880,000 after buying an additional 157,738 shares in the last quarter. Atom Investors LP purchased a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at approximately $122,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Lexicon Pharmaceuticals in the 3rd quarter worth $189,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.